Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
From MaRDI portal
Publication:6577811
DOI10.1214/23-STS895MaRDI QIDQ6577811
Publication date: 24 July 2024
Published in: Statistical Science (Search for Journal in Brave)
Cites Work
- Title not available (Why is that?)
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- A Bayesian dose-finding design for drug combination trials with delayed toxicities
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Cumulative cohort design for dose-finding
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method
- Robust EM Continual Reassessment Method in Oncology Dose Finding
- Design and Analysis of Phase I Clinical Trials
- Coherence principles in dose-finding studies
- The Calculation of Posterior Distributions by Data Augmentation
- Consistency of continual reassessment method under model misspecification
- Continual Reassessment Method: A Likelihood Approach
- Semiparametric Dose Finding Methods
- A Curve‐Free Method for Phase I Clinical Trials
- Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities
- TITE-BOIN12: a Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy
- Bayesian optimal interval designs for phase I clinical trials
- Semiparametric dose finding methods: special cases
- A Bayesian model-free approach to combination therapy phase I trials using censored time-to-toxicity data
- Bayesian uncertainty-directed dose finding designs
- Dose-finding designs: the role of convergence properties
This page was built for publication: Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6577811)
